- Gilead Sciences (NASDAQ:GILD) has completed its $4.3B acquisition of CymaBay Therapeutics (NASDAQ:CBAY).
- However, the biopharma said that the transaction will be considered an asset acquisition and reduce the company’s GAAP and non-GAAP 2024 EPS by approximately $3.10 – $3.20.
- In addition, due to acquisition costs, associated operating expenses and lower interest income, Gilead expects the deal will reduce its GAAP and non-GAAP 2024 EPS by approximately $3.35 – $3.45 relative to the full year 2024 guidance released in early February.
Trending
- ‘I want to die “young” as late as possible,’ says 83-year-old triathlete doctor who reinvented himself after a midlife crisis
- 10 Israeli Soldiers Hospitalized After Wasp Swarm Attack
- Construction Partners posts strong Q2 amid high demand By Investing.com
- ZIM Integrated sails to top industrial gainer of week, Builders FirstSource sees loser tag
- US Marine Says 40% of Drones the IDF Has Shot Down Were Their Own
- Amprius Technologies doubles customer base, boosts revenue By Investing.com
- My 19-year-old son wants to get married so Uncle Sam will ‘kick in more scratch’ for his girlfriend’s financial aid. Is this a terrible idea?
- Meet the Doomsayers Waiting for the Economy to Crash